摘要
目的:探究贝伐单抗(BEV)联合化疗对耐受性较差的复发性卵巢癌患者的临床疗效及安全性。方法:将2015年2月—2017年2月接受治疗的耐受性较差的卵巢癌患者108例分为两组,每组54例。对照组采用多柔比星脂质体或拓扑替康或吉西他滨单药化疗,观察组采用BEV联合多柔比星脂质体或拓扑替康或吉西他滨化疗,观察比较两组临床疗效、不良反应发生情况及预后恢复情况。结果:观察组总有效率高于对照组,差异有统计学意义(P<0.05);两组不良反应发生率和住院时间比较,差异无统计学意义(P>0.05);观察组预后复发时间明显长于对照组,差异有统计学意义(P<0.05);观察组复发时间间隔明显长于对照组,差异有统计学意义(P<0.05)。结论:BEV联合化疗对耐受性较差的复发性卵巢癌患者疗效明显,且无严重不良反应,复发时间长,可提高患者生存质量。
Objective:To investigate the efficacy and safety of bevacizumab(BEV)combined with chemotherapy in patients with poorly tolerated recurrent ovarian cancer.Methods:All 108 patients with poorly tolerated recurrent ovarian cancer admitted to our hospital were selected and divided into two groups,54 cases in each group.The control group received liposomal doxorubicin,topotecan or gemcitabine monotherapy,based on the treatment of control group,the study group received the bevacizumab(BEV).Then the clinical efficacy,adverse reactions and prognosis of the two groups were observed and compared.Results:The total effective rate of the study group was higher than that of the control group(P<0.05).The incidence of adverse reactions showed no statistic difference between the study group and the control group(P>0.05).The recurrence time of the study group after chemotherapy was significantly longer than that of the control group(P<0.05).The time interval of recurrence in the study group was significantly longer than that in the control group(P<0.05).Conclusion:The application of the BEV combined with chemotherapy has the advantages of non-serious adverse reactions,short recurrence time,which can improve the quality of life.
作者
田亚文
TIAN Yawen(Luoyang Central Hospital Affiliated to Zhengzhou University,Luoyang 471003,China)
出处
《临床医药实践》
2020年第5期346-348,共3页
Proceeding of Clinical Medicine
关键词
贝伐单抗联合化疗
复发性卵巢癌
安全性
疗效
bevacizumab combined with chemotherapy
recurrent ovarian cancer
safety
efficacy
